206 related articles for article (PubMed ID: 6205806)
21. Angiogenesis and anti-angiogenic molecularly targeted therapies in malignant gliomas.
Argyriou AA; Giannopoulou E; Kalofonos HP
Oncology; 2009; 77(1):1-11. PubMed ID: 19439998
[TBL] [Abstract][Full Text] [Related]
22. Human glioma associated intermediate filament proteins: over-expression, co-localization and cross-reactivity.
Abaza MS; Shaban F; Narayan RK; Atassi MZ
Anticancer Res; 1998; 18(2B):1333-40. PubMed ID: 9615812
[TBL] [Abstract][Full Text] [Related]
23. Effect of human skin-derived stem cells on vessel architecture, tumor growth, and tumor invasion in brain tumor animal models.
Pisati F; Belicchi M; Acerbi F; Marchesi C; Giussani C; Gavina M; Javerzat S; Hagedorn M; Carrabba G; Lucini V; Gaini SM; Bresolin N; Bello L; Bikfalvi A; Torrente Y
Cancer Res; 2007 Apr; 67(7):3054-63. PubMed ID: 17409412
[TBL] [Abstract][Full Text] [Related]
24. Two novel cell specific receptor proteins, CRLR and CD 117 in human glial tumors.
Mennel HD; Hallier-Neelsen M; Hagner S; Benes L
Clin Neuropathol; 2006; 25(3):107-14. PubMed ID: 16719406
[TBL] [Abstract][Full Text] [Related]
25. Angiogenesis in malignant gliomas.
Plate KH; Risau W
Glia; 1995 Nov; 15(3):339-47. PubMed ID: 8586468
[TBL] [Abstract][Full Text] [Related]
26. Increased angiogenic capabilities of endothelial cells from microvessels of malignant human gliomas.
Bian XW; Jiang XF; Chen JH; Bai JS; Dai C; Wang QL; Lu JY; Zhao W; Xin R; Liu MY; Shi JQ; Wang JM
Int Immunopharmacol; 2006 Jan; 6(1):90-9. PubMed ID: 16332517
[TBL] [Abstract][Full Text] [Related]
27. Downregulating FPR restrains xenograft tumors by impairing the angiogenic potential and invasive capability of malignant glioma cells.
Chen DL; Ping YF; Yu SC; Chen JH; Yao XH; Jiang XF; Zhang HR; Wang QL; Bian XW
Biochem Biophys Res Commun; 2009 Apr; 381(3):448-52. PubMed ID: 19233142
[TBL] [Abstract][Full Text] [Related]
28. Glial fibrillary acidic protein and fibronectin expression in human gliomas.
Cuccurullo L; Agozzino L; Rossiello R; Mignini R; Ferraraccio F
Acta Neurol (Napoli); 1984 Jun; 6(3):176-85. PubMed ID: 6475583
[No Abstract] [Full Text] [Related]
29. Angiostatin suppresses malignant glioma growth in vivo.
Kirsch M; Strasser J; Allende R; Bello L; Zhang J; Black PM
Cancer Res; 1998 Oct; 58(20):4654-9. PubMed ID: 9788618
[TBL] [Abstract][Full Text] [Related]
30. Evidence that Cereport's ability to increase permeability of rat gliomas is dependent upon extent of tumor growth: implications for treating newly emerging tumor colonies.
Bartus RT; Snodgrass P; Dean RL; Kordower JH; Emerich DF
Exp Neurol; 2000 Jan; 161(1):234-44. PubMed ID: 10683290
[TBL] [Abstract][Full Text] [Related]
31. Human glioma-mesenchymal extracellular matrix antigen defined by monoclonal antibody.
Bourdon MA; Wikstrand CJ; Furthmayr H; Matthews TJ; Bigner DD
Cancer Res; 1983 Jun; 43(6):2796-805. PubMed ID: 6342760
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of intracerebral glioblastoma growth by local treatment with the scatter factor/hepatocyte growth factor-antagonist NK4.
Brockmann MA; Papadimitriou A; Brandt M; Fillbrandt R; Westphal M; Lamszus K
Clin Cancer Res; 2003 Oct; 9(12):4578-85. PubMed ID: 14555533
[TBL] [Abstract][Full Text] [Related]
33. Expression of complement membrane regulators membrane cofactor protein (CD46), decay accelerating factor (CD55), and protectin (CD59) in human malignant gliomas.
Mäenpää A; Junnikkala S; Hakulinen J; Timonen T; Meri S
Am J Pathol; 1996 Apr; 148(4):1139-52. PubMed ID: 8644856
[TBL] [Abstract][Full Text] [Related]
34. Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas.
Nakamizo A; Marini F; Amano T; Khan A; Studeny M; Gumin J; Chen J; Hentschel S; Vecil G; Dembinski J; Andreeff M; Lang FF
Cancer Res; 2005 Apr; 65(8):3307-18. PubMed ID: 15833864
[TBL] [Abstract][Full Text] [Related]
35. Endogenous expression of transforming growth factor beta1 inhibits growth and tumorigenicity and enhances Fas-mediated apoptosis in a murine high-grade glioma model.
Ashley DM; Kong FM; Bigner DD; Hale LP
Cancer Res; 1998 Jan; 58(2):302-9. PubMed ID: 9443409
[TBL] [Abstract][Full Text] [Related]
36. Establishment and characterization of a cell line from a human gliosarcoma.
Rutka JT; Giblin JR; Høifødt HK; Dougherty DV; Bell CW; McCulloch JR; Davis RL; Wilson CB; Rosenblum ML
Cancer Res; 1986 Nov; 46(11):5893-902. PubMed ID: 3019542
[TBL] [Abstract][Full Text] [Related]
37. Products of cells cultured from gliomas. VI. Immunofluorescent, morphometric, and ultrastructural characterization of two different cell types growing from explants of human gliomas.
McKeever PE; Smith BH; Taren JA; Wahl RL; Kornblith PL; Chronwall BM
Am J Pathol; 1987 May; 127(2):358-72. PubMed ID: 3555104
[TBL] [Abstract][Full Text] [Related]
38. Angiogenesis and invasion in glioma.
Onishi M; Ichikawa T; Kurozumi K; Date I
Brain Tumor Pathol; 2011 Feb; 28(1):13-24. PubMed ID: 21221826
[TBL] [Abstract][Full Text] [Related]
39. Cell kinetics of glial tumors.
Hoshino T
Rev Neurol (Paris); 1992; 148(6-7):396-401. PubMed ID: 1448658
[TBL] [Abstract][Full Text] [Related]
40. Molecular and genetic profiling in human gliomas.
Palanichamy K; Erkkinen M; Saia G; Chakravarti A
Discov Med; 2007 Jun; 7(38):75-81. PubMed ID: 18093469
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
